Pharmaceutical

India’s pharmaceutical sector is witnessing a significant development as Eris Lifesciences and Natco Pharma have introduced a generic version of Semaglutide, a widely used treatment for Type 2 Diabetes. The launch could improve affordability and access to advanced diabetes therapies across the country. Semaglutide-based medicines have gained global attention not only for managing blood glucose levels but also for their role in weight management.

India’s pharmaceutical sector has marked a significant milestone with the launch of a generic version of semaglutide, a widely recognized drug used to treat Type 2 diabetes and aid weight management. The introduction of the generic formulation is expected to significantly reduce treatment costs, potentially improving access for millions of patients struggling with metabolic disorders.

Indian pharmaceutical company Mankind Pharma has acquired the rights to the well-known neurological medication brand Rivotril from Roche India, marking a significant strategic move in the country’s pharmaceutical landscape. The transaction is expected to strengthen Mankind Pharma’s presence in the central nervous system (CNS) therapy segment, one of the fastest-growing areas in healthcare.

Indian pharmaceutical companies Zydus Lifesciences and Lupin Limited have announced a strategic collaboration to develop and commercialize Semaglutide, a widely recognized therapy for managing type 2 diabetes. The partnership highlights a growing trend among domestic drug manufacturers to collaborate on high-value treatments in rapidly expanding therapeutic markets. With diabetes cases rising globally and particularly in India, the initiative could strengthen the companies’ presence in the lucrative metabolic disease segment.

Zydus Lifesciences has received regulatory approval in China for its innovative drug Desidustat, a treatment designed to address renal anemia in patients suffering from chronic kidney disease (CKD). The approval from China’s National Medical Products Administration (NMPA) represents a significant milestone for the Indian pharmaceutical company as it expands its presence in one of the world’s largest healthcare markets. The drug will be commercialized through an exclusive licensing agreement with a subsidiary of China Medical System Holdings Ltd.

India is taking a decisive step toward strengthening its domestic pharmaceutical supply chain with the foundation of a Rs 600 crore manufacturing facility in Kathua district of Jammu and Kashmir. The project, developed by Orchid Pharma with support from the Biotechnology Industry Research Assistance Council under the Department of Biotechnology, will produce Amino Cephalosporanic Acid (ACA), a vital intermediate used in cephalosporin antibiotics.